Salute e Benessere

New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult…

In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) levelversus baseline in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were switched from anti-C5 therapies (Hb≥ 10g/dL following treatment with eculizumab or ravulizumab)1 ,2PNH is a rare, chronic and serious complement-mediated blood disorder, characterized by hemolysis, anemia, thrombosis and other symptoms, and patients are often treated with...

Press Release: Sequana Medical announces decision of major shareholders to…

SEQUANA MEDICAL ANNOUNCES DECISION OF MAJOR SHAREHOLDERS TO INVEST IN SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN Ghent, Belgium, 6 December 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that five of its major shareholders, namely Partners in Equity V B.V. (" Partners in Equity "), EQT Health Economics 3 Coöperatief U.A…

SR_A HUBLOT 3.0 IN PARTNERSHIP WITH DR SAMUEL ROSS MBE

NYON, Switzerland , Dec. 6, 2024 /PRNewswire/ -- For 44 years, Hublot has been incessantly innovating, pushing the technical and aesthetic boundaries of its models. A subtle balance between watchmaking expertise and a vision of the future, Hublot timepieces are stunningly contemporary. This success has been made possible by cutting-edge research into materials and collaborations with some of the world's leading artists and designers. Samuel Ross has spectacularly combined these two aspects. ...

WuXi Biologics Achieves Major Milestones at Ireland Site with Multiple 16,000L…

The GMP authorization was granted by HPRA following a comprehensive on-site inspection in October 2024, which evaluated the GMP oversight of all data, processes, personnel, manufacturing, storage, and analytical areas across the multi-product facility. The granting of this approval provides WuXi Biologics the opportunity to expand its services to support the unmet needs of patients worldwide and highlights the commitment to comply with standards and legislation allowing it to release clinical…

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Teva entered into an agreement with JKI Co., Ltd. ( “JKI” ) established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ("J-Will”), through which JKI will acquire Teva-TakedaThe agreement is aligned with Teva's Pivot to Growth strategy to focus its businessThe expected divestment of Teva-Takeda, Teva's business venture in Japan, which includes generics products and legacy products, will allow Teva to focus on bringing its innovative medicines to the...

Global Pelvic Floor Stimulation Devices Market to Observe Stunning Growth at a…

Key Takeaways from the Pelvic Floor Stimulation Devices Market Report Key Takeaways from the Pelvic Floor Stimulation Devices Market Report To read more about the latest highlights related to the pelvic floor stimulation devices market, get a snapshot of the key highlights entailed in the Global Pelvic Floor Stimulation Devices Market Report Pelvic Floor Stimulation Devices Overview Pelvic floor stimulation devices are medical tools designed to strengthen the pelvic floor...

PHAXIAM Therapeutics : monthly information related to total number of voting…

Article 223-16 of general regulation of French Autorité des Marchés FinanciersListing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM)Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut(1)voting rightsTotal of net(2)voting rights December 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 951...

Myant and Coapt Partner to Transform Assistive Technology and Pain Management…

"Myant and Coapt share a vision of improving quality of life through seamless integration between technology and the human body," said Tony Chahine, CEO at Myant. "This collaboration will push the boundaries of what is possible in prosthetics and rehabilitation." "Myant and Coapt share a vision of improving quality of life through seamless integration between technology and the human body," saidTony Chahine, CEO at Myant. "This collaboration will push the…

New generation steps up to continue IBA's entrepreneurial ownership

Louvain-la-Neuve, Belgium, 5 December 2024 -IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, announces today an initiative aimed at perpetuating the entrepreneurial anchoring of its shareholder base. A new generation of executives will acquire a significant indirect stake in IBA. It is part of a broader strategy to ensure IBA's growth, value creation and sustainability. Company's success originates from a unique combination between entrepreneurial...

Coloplast A/S - Decisions at the Annual General Meeting 2024

/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2023/24 was approved.Distribution of year-end dividend of DKK 17.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S' half- year result, this brings the total dividend paid for the financial year 2023/24 to DKK 22.00 per share of nominally DKK 1...

Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of…

Søren Tulstrup, President and CEO, Hansa Biopharma said, "We are very pleased with the fast enrolment of all 50 patients in the GOOD-IDES-02 trial. The completion of patient enrolment in this pivotal Phase 3 trial is an important milestone in our efforts to investigate the potential role for imlifidase to address the high unmet need in anti-GBM. The majority of patients with anti-GBM today lose kidney function and two-thirds experience kidney failure requiring long-term dialysis. We look…

AtomVie Global Radiopharma Appoints Dr. Pratibhash Chattopadhyay as Chief…

This cutting-edge facility will increase production capacity by over tenfold, empowering AtomVie to meet the escalating global demand for radiopharmaceuticals. With unmatched expertise and a proven track record, AtomVie is well positioned to provide clinical and commercial manufacturing support, working hand-in-hand with partners to deliver high quality radiopharmaceuticals transforming patients' lives. This cutting-edge facility will increase production capacity by over tenfold, empowering...

Jiva Technologies Initiates Production of LIV3's SugarShield Supplement with…

Chris Mearns, founder of LIV3, expressed his excitement:"Placing our first order with one of the best supplement producers in the industry is a dream come true. We're one step closer to bringing SugarShield to life and helping people curb their cravings while managing sugar intake. We believe this will have a tremendous impact on overall health and weight management." Chris Mearns, founder of LIV3, expressed his excitement:"Placing our first order with one of the best supplement…

Field Medical's FieldForce™ Ablation System Earns FDA TAP Pilot Acceptance and…

Dr. Vivek Reddy, Director of Electrophysiology at Mount Sinai Health System, added, "The FDA's recognition of this breakthrough technology underscores the urgent need for innovation in treating complex, life-threatening ventricular tachycardia. Field Medical's ablation system has the potential to redefine VT care for physicians and patients alike." Dr.Vivek Reddy, Director of Electrophysiology at Mount Sinai Health System, added, "The FDA's recognition of this breakthrough…

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of…

announcedthe completion of target enrollment into the multinational VIRAGE Phase 2b clinical study evaluating intravenous VCN-01 in combination with gemcitabine/nab-paclitaxel as a first line therapy for PDAC patients.Type D meetings are focused on a narrow set of issues that are used to discuss issues at key decision points to provide timely feedback critical to moving a drug development program forward. The FDA advised that the on-going VIRAGE Phase 2b study should not be expanded into...

BioVaxys Shares New Data on its DPX™ Immune Educating Platform at Personalized…

Unique Potential for DPX in New Fields of Use Unique Potential for DPX in New Fields of Use VANCOUVER, BC , Dec. 5, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") presented a new study today at the Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) inBoston, MA, that supports further differentiation of its DPX immune educating platform from current aqueous, emulsion, and LNP...

LifeSignals Receives EU MDR Certification for UbiqVue™ 2A Multiparameter System

Central to the system is the UbiqVue 2A Biosensor, a single-use, all-in-one wearable device that enables SpO 2 ** to be continuously collected from the chest, alongside other biodata, for generating a total of twelve monitored parameters, including 2-channel ECG, pulse rate, PPG, respiration rate, body temperature, and motion. The encrypted data is securely transmitted, in near real-time, from the Biosensor via a relay app or an access point to a secure cloud-based system, where it...

Oncoinvent ASA announces oversubscribed private placement

The bookbuilding process was managed by Carnegie AS and DNB Markets, a part of DNB Bank ASA (the 'Managers'), and the Private Placement attracted significant interest from both existing shareholders, new investors and management. The transaction was upsized during the bookbuilding period from NOK 100 million to NOK 130 million due to high demand. The bookbuilding process was managed by Carnegie AS and DNB Markets, a part of DNB Bank ASA (the 'Managers'), and the Private Placement attracted...

Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator…

"We are excited to support Lilly's mission to enable external biotech collaborators to expedite their product development," commented Brandon Fincher, President of Early Stage Development & Testing at Cambrex. "Our Longmont facility offers all services required to advance early stage small molecules into the clinic with speed, flexibility and scientific excellence. We look forward to propelling Lilly Cataylze360 collaborators forward on an efficient path to success with their…

NTC presents positive results from Phase II Mirakle study evaluating an…

"These interim findings reaffirm that NTC014 is eligible to be a new treatment for bacterial conjunctivitis", Alessandro Colombo, Chief Scientific Officer, NTC, states. "We aim at demonstrating with robust clinical evidence value and potential for NTC014, considering also that this drug responds to our mission to contribute to fighting antibiotic resistance by using less antibiotics, for a shorter treatment duration with no limitation of usage, also in case of non-confirmation of…

Magstim Horizon Inspire Transcranial Magnetic Stimulation Device Approved by…

UK System for Patient Treatment of MDD, OCD and Decreasing Anxiety* “As the first to introduce clinical TMS into the NHS, our team continues delivering innovative treatments to help treat depression and anxiety,” said Professor Alex O'Neill Kerr, MBChB, Medical Director of Transforming Mind Solutions. “This new system takes trusted Magstim TMS technology to the next level, improving patient outcomes.”“Magstim has supplied the NHS with TMS technology for more than 30 years,” said...

LG Chem and Acies Bio Collaborate to Advance Sustainable Production of Chemicals

The partnership leverages Acies Bio's OneCarbonBio TMmicrobial platform for innovative production methods based on biotechnology.The collaboration focuses on creating sustainable solutions using renewable or recycled one-carbon feedstock as raw materials that do not compete with the food chain.The goal is to develop commercially scalable technology for producing industrial chemicals.LJUBLJANA, Slovenia and SEOUL, South Korea, Dec.05, 2024(GLOBE NEWSWIRE) -- LG Chem, one of the...

Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the…

Under the terms of the agreement, Eckert & Ziegler will supply Ariceum with the required quantities of non-carrier-added (n.c.a.) Ac-225 and Lu-177. Both radionuclides will be used to radiolabel Ariceum's proprietary lead radiopharmaceutical drug (SS0110) satoreotide targeting hard-to-treat cancers in clinical studies and subsequent commercial phases. The agreement also includes options for expansion to other drugs as well as the use of additional radionuclides in preparation for future…

First patient dosed in EXIST Phase 2a study in Parkinson's disease

"We are very excited that the first patient with Parkinson's disease has now been dosed in the EXIST Phase 2a study with exidavnemab," said Gunilla Osswald, CEO at BioArctic. "It marks an important next step on BioArctic's pioneering journey to broaden our research portfolio and help more patients and families with different neurological disorders to a better life." "We are very excited that the first patient with Parkinson's disease has now been dosed in the EXIST Phase…

Altri Comunicati